Tirzepatide dosing should follow FDA-approved protocols: initiate at 2.5 mg subcutaneously once weekly for four weeks, then increase to 5 mg weekly
Planning was supported by several conference committees, including a Scientific Programme Committee that includes leading health experts from Africa and around the world
Saunders said this change could limit access to tirzepatide for many patients
Wegovy, the weight loss interpretation of Semaglutide, has gained FDA blessing, offering a new option for individualities seeking effective results to manage their weight
Dehydration reduces blood volume, which causes blood pressure to drop when you stand
By Nancy Lapid July 22 (Reuters) The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest